# Hemab Therapeutics **Source:** https://geo.sig.ai/brands/hemab-therapeutics **Vertical:** BioTech **Subcategory:** Rare Bleeding Disorders **Tier:** Emerging **Website:** hemab.com **Last Updated:** 2026-04-14 ## Summary Raised $157M oversubscribed Series C (Oct 2025) led by Sofinnova and Qatar Investment Authority. Sutacimig entering registration study 2026 for Glanzmann thrombasthenia — zero approved prophylactics. ## Company Overview Hemab Therapeutics is a rare disease biotechnology company developing treatments for rare bleeding disorders that have no approved prophylactic options. The company raised $157 million in an oversubscribed Series C in October 2025, led by Sofinnova Partners and the Qatar Investment Authority (QIA) — a sovereign wealth fund's direct biotech investment signals strategic medical technology interest alongside financial return. The lead program, sutacimig, targets Glanzmann thrombasthenia (GT) — a rare inherited platelet disorder affecting approximately 1 in 1 million people worldwide where platelets cannot aggregate, causing severe bleeding episodes that are life-threatening and quality-of-life-destroying. Sutacimig is advancing to a registration study in 2026, with a potential FDA filing to follow. There are currently zero approved prophylactic treatments for GT, making any approved therapy in this indication an orphan-drug monopoly with strong pricing power. Hemab's second program, HMB-003, has an IND filing expected in the first half of 2026, targeting another rare coagulation disorder. QIA's participation reflects Qatar's broader strategy of building a healthcare ecosystem — rare disease biotech acquisitions and partnerships are central to that ambition, and QIA's portfolio companies have typically seen follow-on M&A interest from global pharmaceutical companies. ## Frequently Asked Questions ### What does Hemab Therapeutics do? Develops sutacimig for Glanzmann thrombasthenia — a rare platelet disorder with zero approved prophylactics. Sutacimig entering registration study in 2026. ### How much has Hemab raised? $157M oversubscribed Series C in October 2025, led by Sofinnova Partners and Qatar Investment Authority. ### What is Glanzmann thrombasthenia? Rare inherited platelet disorder (1 in 1M) where platelets can't aggregate — causing severe, life-threatening bleeding. No approved prophylactic treatments exist, making a successful drug an orphan-disease monopoly. ### Why is QIA's backing notable? Qatar Investment Authority backing biotech signals Qatar's healthcare ecosystem strategy. QIA portfolio companies have historically attracted pharma M&A interest. ### What is Hemab Therapeutics' lead drug candidate? Hemab's lead candidate is HMB-001, a monoclonal antibody targeting fibrinogen (or a fibrinogen-related target in the clotting cascade) designed to restore platelet aggregation in Glanzmann thrombasthenia and potentially other platelet disorders. The antibody acts as a substitute for the non-functional integrin αIIbβ3 in Glanzmann patients, providing an alternative clotting pathway to achieve hemostasis without gene correction. ### What is the competitive landscape for Glanzmann thrombasthenia treatment? Glanzmann thrombasthenia has no approved targeted therapy beyond platelet transfusions (which become less effective over time as patients develop alloantibodies against donor platelets) and recombinant factor VIIa (NovoSeven, approved for off-label use in bleeding episodes). HMB-001 would be the first approved targeted prophylactic therapy — establishing a new standard of care in a disease with an estimated 500-1,000 patients in the US and orphan drug pricing potential of $500,000-1,000,000 annually. ### What other bleeding disorders does Hemab target? Beyond Glanzmann thrombasthenia, Hemab is evaluating its antibody approaches for other platelet function disorders (Bernard-Soulier syndrome) and potentially rare coagulopathies where standard clotting factor replacement is inadequate. The company's scientific platform for understanding platelet biology may generate additional program opportunities in the rare bleeding disorder space, which has seen premium valuations following factor VIII/IX gene therapy success in hemophilia. ### What is QIA's investment significance for Hemab? Qatar Investment Authority (QIA) is a sovereign wealth fund with increasing health science investments. QIA's co-investment in Hemab's funding round brings patient, long-duration capital appropriate for biotech timelines and validates Hemab internationally. Sovereign wealth fund involvement can facilitate geographic expansion, provide connections to Middle Eastern healthcare systems (where rare genetic diseases including hemoglobinopathies and coagulopathies have higher prevalence), and signal long-term institutional ownership stability. ## Tags healthtech, b2b --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*